Plopii Files Patent for Paraxanthine-Based Headache Pill to Replace Caffeine in OTC Analgesics
核心洞察
Brooklyn-based biotech company Plopii (搜索) filed U.S. Patent Application No. 19/636,926 covering a novel over-the-counter headache (搜索) pill formulated with paraxanthine (搜索), caffeine's primary metabolite.
The fixed-dose oral formulation combines paraxanthine (搜索) with aspirin and acetaminophen, aiming to reduce side effects associated with caffeine-containing analgesics including jitters, sleep disruption, and rebound headaches.
Paraxanthine (搜索) is identified as the molecule responsible for much of caffeine's cognitive and vascular activity while exhibiting a different anxiety, sleep and tolerance profile.
Brooklyn-based biotechnology company Plopii (搜索) announced it has filed U.S. Patent Application No. 19/636,926 covering a novel over-the-counter headache (搜索) pill formulated with paraxanthine (搜索), caffeine's primary active metabolite. The 40-claim patent application was filed with the United States Patent and Trademark Office in spring 2026, marking what the company describes as the first new structural approach in the OTC headache category in decades.
Novel Formulation Strategy
The patent filing covers a fixed-dose oral formulation that pairs paraxanthine (搜索) with two established analgesics: aspirin and acetaminophen. Plopii (搜索) developed this combination to deliver vasoconstriction and analgesic amplification through paraxanthine in place of caffeine, with the goal of reducing side effects commonly associated with caffeine-containing analgesics.
The targeted side effects include jitters, sleep disruption, dependency, and rebound headache (搜索)—complications that have long been associated with caffeine-based headache medications. By substituting paraxanthine (搜索) for caffeine, the company aims to maintain therapeutic benefits while improving the tolerability profile.
Paraxanthine as Active Metabolite
Paraxanthine (搜索) is the metabolite produced when the human liver breaks down caffeine. Recent peer-reviewed research has identified paraxanthine as the molecule responsible for much of caffeine's cognitive and vascular activity, while exhibiting a different anxiety, sleep, and tolerance profile compared to its parent compound.
This metabolic insight forms the scientific foundation for Plopii (搜索)'s approach to reformulating headache (搜索) medications. The company's strategy leverages the therapeutic benefits of caffeine's primary metabolite while potentially avoiding some of the adverse effects associated with caffeine itself.
Development and Regulatory Path
"This patent application represents the first new structural approach we are aware of in the OTC headache (搜索) category in decades," said Michael Tolmach, Co-Founder and Chief Executive Officer of Plopii (搜索). "Filing the patent is a critical step toward bringing this product to consumers."
The product remains in development and is patent-pending. Plopii (搜索) indicated it will share commercial, pricing, and regulatory updates in future announcements as the development program progresses.
Company Background
Plopii (搜索) is a biotechnology company specializing in consumer wellness products and drug patent development centered on paraxanthine (搜索). Headquartered in Brooklyn, New York, the company holds and is pursuing intellectual property covering paraxanthine-based formulations across various therapeutic applications.
The company has issued forward-looking statements noting that patent applications may be amended, narrowed, or rejected during examination, and that product development plans remain subject to change throughout the regulatory process.